ArticleJournal of the National Cancer Institute2017
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Causal associations between Sjögren's syndrome and subtypes of endometrial cancer.BMC immunology · 2026Pooled it
- Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.International journal of cancer · 2025Article
- Expression and clinical significance of RHCG in endometrial cancer.Histology and histopathology · 2024Article
- A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study.Translational cancer research · 2024Article
- CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis.The Journal of clinical investigation · 2022Article
- The prognostic value of arachidonic acid metabolism in breast cancer by integrated bioinformatics.Lipids in health and disease · 2022Article
- Biological Activity ofInternational journal of molecular sciences · 2022Article
- Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival.Cancer research communications · 2022Article
- Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.Acta pharmaceutica Sinica. B · 2022Review
- The expression level and prognostic value of microRNA-15a-5p in endometrial carcinoma.Translational cancer research · 2021Article
- Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.Cancer biology & therapy · 2020Review
- Aspirin use and endometrial cancer risk: a meta-analysis and systematic review.Annals of translational medicine · 2020Article
- Diversity of Chromanol and Chromenol Structures and Functions: An Emerging Class of Anti-Inflammatory and Anti-Carcinogenic Agents.Frontiers in pharmacology · 2020Review
- Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism.Cell communication and signaling : CCS · 2019Article
- Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion.Advances in pharmacological sciences · 2019Review
- Supervised Machine Learning Predictive Analytics For Triple-Negative Breast Cancer Death Outcomes.OncoTargets and therapy · 2019Article
- Aspirin use and endometrial cancer risk and survival.Gynecologic oncology · 2018Review
- Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses.Cancer causes & control : CCC · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 1 country.
Funding
Abstract
Background: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients. Methods: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors. Recurrences, vital status, and causes of death were obtained from medical records and cancer registries. Fine-Gray semiproportional hazards regression estimated adjusted subhazard ratios (HRs) and 95% confidence intervals (CIs) for associations of NSAID use with endometrial carcinoma-specific mortality and recurrence. Models were stratified by endometrial carcinoma type (ie, type I [endometrioid] vs type II [serous, clear cell, or carcinosarcoma]) and histology. Results: Five hundred fifty endometrial carcinoma-specific deaths and 737 recurrences occurred during a median of five years of follow-up. NSAID use was associated with 66% (HR = 1.66, 95% CI = 1.21 to 2.30) increased endometrial carcinoma-specific mortality among women with type I cancers. Associations were statistically significant for former and current users, and strongest among former users who used NSAIDs for 10 years or longer (HR = 2.23, 95% CI = 1.19 to 4.18, two-sided P trend = .01). NSAID use was not associated with recurrence or endometrial carcinoma-specific mortality among women with type II tumors. Conclusions: In this study, use of NSAIDs was associated with increased endometrial carcinoma-specific mortality, especially in patients with type I tumors. Barring a clear biologic mechanism by which NSAIDs would increase the risk of cause-specific mortality, cautious interpretation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.